Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Lucia Y Chen, Michael Amatangelo, Adolfo Aleman, Oliver Van Oekelen, Tania Nevers, Yongliang Sun, William E. Pierceall, Katerina Kappes, Anna Blangiardo, Sundar Jagannath, Cesar Rodriguez, Samir Parekh

Blood (2024) 144 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2024-211651

Published: 2024

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Blood (2023) 142 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2023-184409

Published: 2023

Journal Articles

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Joshua White, Sara Zhukovsky, Edward R Scheffer Cliff, Rajshekhar Chakraborty, Luciano Costa, Oliver Van Oekelen, Doug Sborov, Ghulam Rehman Mohyuddin

Blood (2023) 142 (Supplement 1): 2402.

https://doi.org/10.1182/blood-2023-185175

Published: 2023

Journal Articles

Cellular Mechanisms Associated with Suboptimal Immune Responses to Sars-Cov-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

Adolfo Aleman, Morgan Van Kesteren, Ariel Kogan Zajdman, Komal Srivastava, Lucia Y Chen, Bhaskar Upadhyaya, Jessica Nardulli, Kseniya Serebryakova, Katerina Kappes, Hayley Jackson, Charles Gleason, Oliver Van Oekelen, Carlos Cordon-Cardo, Ania Wajnberg, Florian Krammer, Miriam Merad, Sundar Jagannath, Viviana Simon, Samir Parekh

Blood (2023) 142 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2023-187260

Published: 2023

Journal Articles

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Blood (2023) 141 (7): 756–765.

https://doi.org/10.1182/blood.2022017848

Published: 2023

Includes: Supplemental data

Journal Articles

Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

Adolfo Aleman, Ariel Kogan Zajdman, Yogita Ghodke-Puranik, Bhaskar Upadhyaya, Tarek H. Mouhieddine, Oliver Van Oekelen, Larysa Sanchez, Shambavi Richard, Adriana Rossi, Joshua Richter, Hearn J. Cho, Cesar Rodriguez, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2022) 140 (Supplement 1): 4193–4195.

https://doi.org/10.1182/blood-2022-169538

Published: 2022

Journal Articles

Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination

Ariel Kogan Zajdman, Adolfo Aleman, Bhaskar Upadhyaya, Katherine F. Beach, Kseniya Serebryakova, Sarita Agte, Katerina Kappes, Charles R. Gleason, Komal Srivastava, Oliver Van Oekelen, Carlos Cordon-Cardo, Florian Krammer, Miriam Merad, Sundar Jagannath, Ania Wajnberg, Viviana Simon, Samir Parekh

Blood (2022) 140 (Supplement 1): 4364–4365.

https://doi.org/10.1182/blood-2022-169572

Published: 2022

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Oliver Van Oekelen, Tarek H. Mouhieddine, Darren Pan, Megan Metzger, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Alessandro Lagana, Shambavi Richard, Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2021-152243

Published: 2021

Journal Articles

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Oliver Van Oekelen, Michael Amatangelo, Manman Guo, Bhaskar Upadhyaya, Geoffrey Kelly, Manishkumar Patel, Seunghee Kim-Schulze, Alessandro Lagana, Sarah Gooding, Sundar Jagannath, William E. Pierceall, Udo Oppermann, Samir Parekh, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 730.

https://doi.org/10.1182/blood-2021-151542

Published: 2021

Journal Articles

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Santiago Thibaud, Larysa Sanchez, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 821.

https://doi.org/10.1182/blood-2021-151585

Published: 2021

Journal Articles

Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment

Blood (2021) 138 (Supplement 1): 822.

https://doi.org/10.1182/blood-2021-152365

Published: 2021

Journal Articles

Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma

David T. Melnekoff, Yogita Ghodke-Puranik, Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, Robert Sebra, Sundar Jagannath, Alessandro Lagana, Samir Parekh

Blood (2021) 138 (Supplement 1): 326.

https://doi.org/10.1182/blood-2021-150923

Published: 2021

Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 1775.

https://doi.org/10.1182/blood-2019-126146

Published: 2019

NARROW

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Cellular Mechanisms Associated with Suboptimal Immune Responses to Sars-Cov-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment

Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only